RYXON

This brand name is authorized in Nigeria.

Active ingredients

The drug RYXON contains one active pharmaceutical ingredient (API):

1	Ceftriaxone UNII 023Z5BR09K - CEFTRIAXONE SODIUM
	Ceftriaxone is an antibacterial for systemic use, a third-generation cephalosporin. It inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs) leading to bacterial cell lysis and death.
	Read more about Ceftriaxone

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
C4-0379	Injection	RYXON INJECTION INJ 1 g 1 X 1VIAL	RYXON INJECTION RYXON CEFTRIAXONE 1G POM INJECTION 1 X 1VIAL ANTIBIOTIC PHARMAPLUS NIG. LTD., 7A, NIGER STREET, KANO, KANO STATE. BROOKES PHARMA (PRIVATE) LTD., 58-59, SECTOR NO. 15, KORANGI INDUSTRIAL AREA, KARACHI-74900, PAKISTAN GMP- RBC; LR- FLAF; FEES- PAID; NP:NA 28/11/2017 C4-0379	30/01/2020

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01DD04	Ceftriaxone	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DD Third-generation cephalosporins
Discover more medicines within J01DD04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	C4-0379